Higher pulmonary resistance was associated with worse outcomes in pulmonary hypertension, while SGLT2 inhibitors may improve ...
Treatment with sotatercept — an activin signaling inhibitor — reduced pulmonary vascular resistance (PVR), improved cardiac hemodynamics, and was generally well tolerated in patients with combined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results